

Appendix A
Claim Amendments

1. -5. (Canceled)
6. (Currently amended) ~~[[The]]~~ A pharmaceutical composition comprising the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or a solvate of a physiologically functional derivative thereof and the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, in free combination and in an administration form suitable for inhalative administration by means of a powder inhaler ~~according to Claim 2,~~ wherein the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof and the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, are present in separate pack units, wherein it is possible to take out the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof and the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, from the separate pack units such that they are available for successive inhalative administration.

7. (Currently amended) The pharmaceutical composition according to Claim 6 **[[2]]**, wherein the active compound ciclesonide is present as its R epimer in an amount greater than 95%.
8. (Currently amended) The pharmaceutical composition according to Claim 6 **[[2]]**, wherein the active compound ciclesonide is present as its R epimer in an amount greater than 95%, and the active compound R,R-formoterol is present as a hydrate, salt or hydrate of a salt thereof.
9. (Previously presented) The pharmaceutical composition according to Claim 8, wherein the active compound R,R-formoterol is present as a salt with an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulphuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl) benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic, methanesulphonic acid and 1-hydroxy-2-naphthoic acid.
10. (Previously presented) The pharmaceutical composition according to claim 9, wherein the acid is fumaric acid or tartaric acid.
11. (Currently amended) A method of treating an airway disease in a patient comprising administering to a

patient in need thereof a therapeutically effective amount of the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof in fixed or free combination and in an administration form suitable for inhalative administration by means of a powder inhaler with the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, wherein the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof and the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, are present in separate pack units, wherein it is possible to take out the active compound ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof and the active compound R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof, from the separate pack units such that they are available for successive inhalative administration.

12. (Canceled)

13. (Previously presented) The method according to Claim 11, wherein the active compound ciclesonide is present as its R epimer in an amount greater than 95%.

14. (Currently amended) A method of treating an airway disease in a patient comprising administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 6 ~~[[2]]~~ by means of a dry powder inhaler.
15. (Previously presented) The method according to claim 14, wherein the airway disease is selected from the group consisting of bronchitis, obstructive bronchitis, COPD (chronic obstructive pulmonary disease), spastic bronchitis, allergic bronchitis, allergic asthma and bronchial asthma.
16. (Previously presented) The method according to claim 14, wherein ciclesonide or a solvate, epimer, physiologically functional derivative or solvate of a physiologically functional derivative thereof is administered in a dose of 0.05 to 1 mg per day and R,R-formoterol or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt thereof is administered in a dose of 10 to 50 µg per day.
17. (Previously presented) The method according to claim 16, wherein the dose is administered once daily.
18. -24. (Canceled)